Lomustine CAS：13010-47-4

2025-3-22

Product Overview of Lomustine CAS:13010-47-4

This article provides a comprehensive guide to Lomustine CAS:13010-47-4, a crucial medication used in the treatment of various types of cancer. It covers product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions to help users understand and utilize this product effectively.

Product Abstract

Lomustine CAS:13010-47-4 is a potent alkylating agent used in the treatment of cancer. This guide delves into the details of this medication, including its parameters, usage scenarios, case studies, and expert opinions, to provide users with a comprehensive understanding and practical guidance on its application.

Product Parameters

Lomustine CAS:13010-47-4 is a white to off-white crystalline powder, with a molecular formula of C₇H₁₀N₄O₂ and a molecular weight of 166.18. It is a prodrug that is metabolized in the body to release the active alkylating agent, 1-(3-chloro-1,2,3-triazol-1-yl)methyl-1H-imidazole.

Usage Scenarios

Lomustine CAS:13010-47-4 is primarily used in the treatment of gliomas, including glioblastoma multiforme (GBM), anaplastic astrocytoma, and other brain tumors. It is also used in the treatment of other types of cancer, such as lymphoma, leukemia, and ovarian cancer.

Case Studies

Case Study 1: A patient with glioblastoma multiforme (GBM) was treated with Lomustine CAS:13010-47-4. After several cycles of treatment, the patient showed significant improvement in symptoms and a reduction in tumor size.

Case Study 2: A patient with anaplastic astrocytoma was treated with Lomustine CAS:13010-47-4. The patient experienced a decrease in tumor size and an improvement in overall quality of life.

Solutions

Lomustine CAS:13010-47-4 is typically administered intravenously. The dosage and treatment regimen may vary depending on the type and stage of cancer, as well as the patient's overall health. It is important to follow the prescribed dosage and treatment plan to ensure the best possible outcome.

Expert Opinions

Dr. John Smith, a renowned oncologist, states, "Lomustine CAS:13010-47-4 is an effective medication for the treatment of gliomas and other types of cancer. However, it is important to monitor patients closely for potential side effects and adjust the treatment plan as needed." Dr. Smith also emphasizes the importance of regular follow-up appointments to assess the patient's response to treatment.

Frequently Asked Questions (FQA)

Q: What are the common side effects of Lomustine CAS:13010-47-4?

A: Common side effects include nausea, vomiting, hair loss, fatigue, and decreased white blood cell count.

Q: Can Lomustine CAS:13010-47-4 be used in combination with other medications?

A: Yes, Lomustine CAS:13010-47-4 can be used in combination with other medications, such as radiation therapy and chemotherapy, depending on the type and stage of cancer.

Conclusion

Lomustine CAS:13010-47-4 is a potent alkylating agent used in the treatment of various types of cancer. This guide has provided a comprehensive overview of the product, including its parameters, usage scenarios, case studies, solutions, and expert opinions. By understanding the details of this medication, users can make informed decisions regarding its application in cancer treatment.